article thumbnail

Non-stop investment from CMOs and US Government into continuous manufacturing

Pharmaceutical Technology

In the last year, well-known contract manufacturing organisations (CMOs) such as Agilent Technologies (Santa Clara, California) and Abzena (Cambridge, UK) have expanded their continuous manufacturing capabilities. US Congress is also making substantial investments to improve the continuous manufacturing of pharmaceuticals.

article thumbnail

CAMP4’s funding influx paves the way for tapping regulatory RNA to treat urea cycle disorders

Pharmaceutical Technology

In preparation for this, drug manufacturing will begin later this year and will be outsourced to external contract manufacturing organisations (CMOs). CAMP4’s CSO David Bumcrot PhD tells Pharmaceutical Technology that the company plans to see clinical trials go forward for their urea cycle disorder programs late next year.

RNA 245
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bespoke Gene Therapy Consortium Selects 8 Rare Diseases for Clinical Trial Portfolio

XTalks

In 2022, the FDA approved four new gene therapies, and more than a handful are looking to get approval this year for diseases including Duchenne muscular dystrophy (DMD), sickle cell disease (SCD) and hemophilia A.

article thumbnail

FDA clears Polarean’s lung disease diagnostic Xenoview

pharmaphorum

US medtech company Polarean Imaging has secured FDA approval for Xenoview, a drug device combination used alongside magnetic resonance imaging (MRI) to measure how well the lungs are functioning.

article thumbnail

Provention finally gets FDA nod for type 1 diabetes drug teplizumab

pharmaphorum

At its second attempt, Provention Bio has secured FDA approval for teplizumab, as a treatment to delay late-stage type 1 diabetes (T1D) in at-risk individuals – becoming the first disease-modifying therapy for these patients. It is now in line for a $35 million equity investment by Sanofi following FDA approval.

Drugs 52
article thumbnail

Oncorus Pivots to Scale Up Manufacturing with New GMP Facility

The Pharma Data

As Oncorus builds the infrastructure needed, and as needed thereafter, it will continue to utilize contract manufacturing organizations, all with the goal of scaling up for potential commercial launch support, says Chief Operations Officer and Chief of Staff Steve Harbin. Oncorus’ stock opened at $32.45 Monday, up $0.28

article thumbnail

CMO Moves: Regulatory catalysts for therapy manufacturing -January

Pharmaceutical Technology

In order to get a therapy to the market, pharma companies often outsource the drug manufacturing to specialist contract manufacturing organizations (CMOs). Regulatory decisions by the US FDA from late November to mid-December for select therapies, and the CMOs contracted to manufacture them.